Blood discard rate in a blood center in Curitiba – Brazil. Ten years of study

Blood wastage management in a regional blood transfusion centre

“…Analysis of reasons for discarding blood components in central India showed that 1·2% of RBCs or FFP units were discarded due to seropositivity for transfusion‐transmissible infections (TTIs) (Kumar et al ., ). The total blood discard rate due to positive serology in a blood centre in Curitiba‐Brazil was 5% (Monich et al ., ). The screening test results for TTIs in The Netherlands and the Austrian Red Cross Blood Establishment showed that the annual average for repeatedly reactive donations was ∼0·1%.…”

Seroprevalence of Trypanosoma cruzi infection among blood donors in the state of Bahia, Brazil

“…Dias (1998) reported that the seropositivity between 1988 and 1990 in Brazil was 0.97% and decreased in the following years: 0.7-1.1% in 1991, 0.7% in 1993, and 0.75% in 1994; the seropositivity in the northeast of Brazil was 0.36% in 1994. In contrast, Monich (2016) found that the discard rate of donated blood in Curitiba between 2003 and 2012 varied from 0.6% to 0.9%, whereas Slavov et al (2016) indicated that the discard rate in the state of São Paulo between 2012 and 2014 was 0.1%. It is worth mentioning that the methodology used in some studies did not involve second screening, and prevalence was calculated using donors with positive serology in the first screening.…”

“…Serological screening has been used in several countries to improve public health programs. However, this type of testing is facing ethical, operational, and financial difficulties 20 .…”

International Forum on Occult hepatitis B infection and transfusion safety

“…Studies of prevalence of OBI in Brazil depend on the endemicity of the region. It was found as 3·3% among blood donors reactive for anti‐HBc in southern Brazil, 2·7% in north‐eastern and 2·7% in the northern region . It is also important to remember that OBI is more common than infections during the window period, as well as other relevant factors than can cause an impact in the clinical outcome of OBI transmission such as a strict and careful clinical screening of blood donors, excluding high‐risk groups, the recruitment of repeated donors, the recipient's immune response, the number of HBV‐DNA copies in the blood products transfused and the blood product type, once the transmission through plasma is more common than platelets and red blood cells .…”